Vemurafenib resistance reprograms melanoma cells towards glutamine dependence

@article{HernandezDavies2015VemurafenibRR,
  title={Vemurafenib resistance reprograms melanoma cells towards glutamine dependence},
  author={Jenny E Hernandez-Davies and Thai Q. Tran and Michael R. Reid and K. Rosales and X. Lowman and Min Pan and Gatien Moriceau and Y. Yang and J. Wu and R. Lo and M. Kong},
  journal={Journal of Translational Medicine},
  year={2015},
  volume={13}
}
  • Jenny E Hernandez-Davies, Thai Q. Tran, +8 authors M. Kong
  • Published 2015
  • Biology, Medicine
  • Journal of Translational Medicine
  • BackgroundV600BRAF mutations drive approximately 50% of metastatic melanoma which can be therapeutically targeted by BRAF inhibitors (BRAFi) and, based on resistance mechanisms, the combination of BRAF and MEK inhibitors (BRAFi + MEKi). Although the combination therapy has been shown to provide superior clinical benefits, acquired resistance is still prevalent and limits the overall survival benefits. Recent work has shown that oncogenic changes can lead to alterations in tumor cell metabolism… CONTINUE READING
    69 Citations
    Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
    • 36
    • PDF
    HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
    • 2
    • PDF
    Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
    • 4

    References

    SHOWING 1-10 OF 35 REFERENCES
    Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    • 194
    • PDF
    Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    • 692
    • PDF
    Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    • 215
    • PDF
    BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
    • 106
    • Highly Influential
    • PDF
    Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
    • 192
    Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
    • 1,862
    • PDF
    Emerging insights into resistance to BRAF inhibitors in melanoma.
    • 63
    Improved survival with MEK inhibition in BRAF-mutated melanoma.
    • 1,219
    • PDF
    Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
    • 2,112
    • PDF